Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Friedreich ataxia is a rare inherited neurological condition characterized by progressive impairment of coordination and balance, with involvement of the heart, musculoskeletal system, and other organ systems. Per clinical review, the condition is the most common form of early-onset inherited ataxia among individuals of European ancestry, as well as those from the Middle East, South Asia, and North Africa. Prevalence estimates range from approximately 1 to 9 per 100,000 based on clinical diagnosis; lower estimates result from combined clinical and molecular criteria. Per clinical review, mean onset age falls between 10 and 15 years, with a range extending from early childhood through the fifth decade of life and beyond. Three recognized subtypes have been documented: Friedreich ataxia 1, Friedreich ataxia 2, and a variant form characterized by retained reflexes. The Friedreich's Ataxia Research Alliance (FARA) maintains a patient registry and active research infrastructure supporting investigation of this condition.
Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.
The hallmark feature of Friedreich ataxia is gait ataxia, present in all affected individuals and typically representing the earliest manifestation. Per clinical review, initial symptoms include poor balance when walking, followed by slurring of speech (dysarthria) and progressive upper-limb ataxia. Impaired proprioception—reduced awareness of limb position—is very frequently observed (80–99% of cases), as are hand muscle atrophy, limb ataxia, gait imbalance, and Babinski sign. Balance difficulties are often accentuated when visual input is limited, such as in darkness or with eyes closed. Within approximately five years of onset, most individuals develop scanning dysarthria, lower-extremity weakness, and diminished or absent position and vibration sense in the distal extremities. Ankle and knee reflexes are typically absent or diminished in the lower limbs. Skeletal involvement, including scoliosis, foot deformities such as pes cavus and talipes equinovarus, and poor fine motor coordination, is reported in 30–79% of cases. Cardiac involvement, specifically cardiomyopathy and abnormal electrocardiographic findings, occurs in a substantial proportion of individuals and represents a significant source of morbidity. Additional features may include muscle spasm, muscle weakness, restless legs, sensory axonal neuropathy, and urinary bladder sphincter dysfunction.
Explore clinical features
Genetic Landscape
Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.
Friedreich ataxia is an inherited condition arising from pathogenic changes in the genomic region encoding frataxin. Per clinical review, the condition is inherited in an autosomal recessive manner, meaning pathogenic variants must be present on both copies of the relevant chromosomal segment for the condition to manifest. The predominant mechanism is a GAA trinucleotide repeat expansion in the first intron of the frataxin-encoding region; individuals may also carry compound heterozygous configurations combining a GAA repeat expansion with a sequence variant or deletion at the same locus. Per clinical review, frataxin deficiency results in abnormal accumulation of intramitochondrial iron, impaired mitochondrial respiration, and overproduction of oxygen-derived free radicals, contributing to progressive cellular damage in the nervous system and heart. Penetrance is complete across the range of established full-penetrance allele sizes, though the wide variability in repeat length is a primary contributor to the broad age-of-onset range observed across affected individuals.
Diagnosis
Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.
Per clinical review, no consensus diagnostic criteria for Friedreich ataxia have been published. The diagnosis is considered in individuals presenting with progressive neurological features consistent with the condition, including gait ataxia, limb ataxia, impaired proprioception, and dysarthria. Neurophysiological studies, brain and spinal cord imaging, and family history contribute to the clinical assessment. Cardiac evaluation is incorporated into the diagnostic workup given the frequency of cardiomyopathy and electrocardiographic abnormalities in this population. Molecular genetic testing for pathogenic repeat expansions and sequence variants at the frataxin-encoding locus serves as the confirmatory diagnostic approach. The differential diagnosis encompasses other inherited causes of early-onset ataxia and peripheral neuropathy, including the hereditary motor and sensory neuropathies and additional spinocerebellar ataxia syndromes. The broad age range of onset—spanning from early childhood through the fifth decade—may complicate recognition of atypical or late-onset presentations.
Treatment
Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.
Omaveloxolone (brand name SKYCLARYS) received FDA approval in February 2023, representing the first approved disease-modifying therapy for Friedreich ataxia in the United States. The agent targets oxidative stress and mitochondrial dysfunction arising from frataxin deficiency. Per clinical review, no cure exists for Friedreich ataxia, and management beyond this targeted agent is otherwise supportive and multidisciplinary. Neurological, cardiac, musculoskeletal, and metabolic manifestations are addressed through coordinated multidisciplinary care over the course of the condition. Cardiac evaluation and management are integral components of ongoing care given the high frequency of cardiomyopathy among affected individuals. Management of diabetes, scoliosis, and speech and swallowing difficulties is incorporated as manifestations emerge. Numerous agents currently hold orphan drug designations for Friedreich ataxia—including frataxin-level restoration approaches, antioxidant compounds, and gene therapy vectors—but these designations do not confer FDA approval, and these agents are not currently approved for clinical use. Agents to avoid, as identified through clinical review, include substances toxic to peripheral nerves and circumstances that increase fall risk.
Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.
Per clinical review, Friedreich ataxia follows a progressive course, with neurological function declining from the time of symptom onset. Most individuals lose the ability to walk independently within 10 to 15 years of the first symptoms, ultimately requiring wheelchair assistance. Late-onset forms of the condition—defined by symptom onset after age 25 or after age 40—may follow a more protracted clinical course. Per clinical review, cardiac disease, particularly cardiomyopathy, contributes substantially to morbidity and represents a leading cause of premature mortality in this population. Life expectancy is reduced compared to the general population, with the degree of cardiac involvement among the principal determinants of individual outcome. The availability of an FDA-approved targeted therapy represents a meaningful development in the management landscape; the long-term effects of treatment on disease trajectory and functional outcomes continue to be evaluated in ongoing clinical investigations.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
Friedreich ataxia is the subject of a broad and active clinical research effort, with numerous registered trials spanning gene therapy, frataxin protein restoration, neuroprotective agents, digital outcome assessment, and pediatric dosing. Several Phase 2 and Phase 3 studies are currently recruiting or active, including gene therapy investigations targeting cardiac manifestations of the condition and a Phase 3 long-term efficacy evaluation of vatiquinone, an antioxidant compound. Published research activity encompasses basic science and preclinical investigation, biomarker development, and clinical trial outcome reporting, with over 300 classified publications documented in this area. Active frataxin replacement programs—including protein delivery and gene therapy approaches—reflect strong scientific and industry interest in expanding treatment options beyond the currently approved agent. FARA maintains a publicly accessible drug development pipeline cataloguing additional agents across various stages of investigation.
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
Recent research highlights various pharmacological treatments for Friedreich ataxia, focusing on potential therapeutic strategies to manage this rare neurodegenerative disorder. The findings contribute to the understanding of treatment options available for patients.
The FDA is advancing real-time clinical trials, allowing for quicker analysis and submission of trial data, which could significantly expedite the delivery of innovative therapies. Paradigm Health's platform will enable near real-time data sharing, enhancing safety and efficacy monitoring.
Las Vegas Nevada United States As per DelveInsight s assessment globally Netherton Syndrome pipeline constitutes 5 key companies continuously working towards developing 5 Netherton Syndrome treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ... Las Vegas Nevada United States As per DelveInsight s assessment globally Netherton Syndrome pipeline constitutes 5 key companies continuously working towards developing 5 Netherton Syndrome treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ... This represents an important milestone as Quoin progresses its therapeutic candidate into late-stage clinical development. • In April 2025, ResVita Bio, a therapeutics company specializing in skin disease treatments, announced that the FDA has granted Orphan Drug Designation to RVB-003 for Netherton Syndrome, a serious and chronic skin disorder. Building on the FDA's earlier Rare Pediatric Disease Designation, this milestone highlights ResVita Bio's innovative continuous protein therapy platform, which delivers sustained drug levels directly to the skin, offering enhanced efficacy and improved safety compared to conventional topical treatments. • Netherton Syndrome companies working in the treatment market are Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children's Hospital of Philadelphia, and others, are developing therapies for the Netherton Syndrome treatment • Emerging Netherton Syndrome therapies in the different phases of clinical trials are- QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others are expected to have a significant impact on the Netherton Syndrome market in the coming years. • In March 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late-stage specialty pharmaceutical company focused on rare and orphan diseases, announced a clinical and regulatory update following a constructive Type C meeting with the U.S. Press release - DelveInsight Business Research - Netherton Syndrome Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight - published on openPR.com
FDA approves ScinoPharm Taiwan’s glatiramer acetate injection for relapsing multiple sclerosis, marking the first complex injectable generic approval for this therapy. Additionally, Alkermes receives breakthrough therapy designation for alixorexton, an oral treatment for narcolepsy type 1.
